Clinical efficacy analysis of recombinant human erythropoietin in the treatment of lower-risk myelodysplastic syndromes

• Published in: Zhōnghuá xuèyèxué zázhì Vol. 35; no. 1; p. 18
• Main Authors: Zhang, Hongli, Qin, Tiejun, Xu, Zefeng, Fang, Liwei, Pan, Lijuan, Hu, Naibo, Qu, Shiqiang, Zhang, Yue, Xiao, Zhijian
• Format: Journal Article
• Language: Chinese
• Published: China 01.01.2014
• Subjects: Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Erythropoietin - administration & dosage; Erythropoietin - therapeutic use; Female; Granulocyte Colony-Stimulating Factor - administration & dosage; Granulocyte Colony-Stimulating Factor - therapeutic use; Humans; Male; Middle Aged; Myelodysplastic Syndromes - therapy; Recombinant Proteins - administration & dosage; Recombinant Proteins - therapeutic use; Retrospective Studies; Treatment Outcome; Young Adult
• ISSN: 0253-2727
• DOI: 10.3760/cma.j.issn.0253-2727.2014.01.006

To investigate the efficacy and impact factors in lower-risk [International prognostic scoring system (IPSS) low or intermediate-1 risk] myelodysplastic syndrome (MDS) patients treated with recombinant human erythropoietin (rhEPO) alone or in combination with recombinant human granulocyte colony- stimulating factor (rhG-CSF). A total of 52 consecutive lower-risk MDS patients received subcutaneous injection of rhEPO alone or in combination with rhG-CSF at least 8 weeks, the rhEPO dose would be reduced slowly to stop or kept at minimum to maintain the response when the best efficacy achieved and maintained for 4 weeks. Their clinical features, efficacy, survival and the predictors of efficacy were analyzed retrospectively. The overall response rate was 51.9% (27/52) with 33.3%(9/27) achieving complete remission (CR) and 66.7%(18/27) achieving erythroid response (HI-E). In multivariate analysis, sEPO level (less than 500 U/L), BFU-E count (more than 25/10⁵ BMMNC), intermediate and high doses rhEPO±rhG-CSF therap